EPO and chronic kidney disease: This section synthesizes the mechanisms by which current therapeutic interventions (including EPO and its analogs, nitric oxide (NO) donors, and antioxidants) counteract accelerated eryptosis, thereby extending RBC survival and alleviating renal anemia, while also discussing their clinical utility, limitations, and relevance across CKD stages.